PL3389662T3 - Sposób wytwarzania trójpierścieniowych związków inhibitorów pi3k oraz sposoby ich zastosowania do leczenia raka - Google Patents
Sposób wytwarzania trójpierścieniowych związków inhibitorów pi3k oraz sposoby ich zastosowania do leczenia rakaInfo
- Publication number
- PL3389662T3 PL3389662T3 PL16876773T PL16876773T PL3389662T3 PL 3389662 T3 PL3389662 T3 PL 3389662T3 PL 16876773 T PL16876773 T PL 16876773T PL 16876773 T PL16876773 T PL 16876773T PL 3389662 T3 PL3389662 T3 PL 3389662T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- preparation
- treatment
- methods
- same
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268149P | 2015-12-16 | 2015-12-16 | |
| US201662288832P | 2016-01-29 | 2016-01-29 | |
| US201662291248P | 2016-02-04 | 2016-02-04 | |
| EP16876773.9A EP3389662B1 (en) | 2015-12-16 | 2016-12-16 | Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer |
| PCT/US2016/067174 WO2017106647A1 (en) | 2015-12-16 | 2016-12-16 | Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3389662T3 true PL3389662T3 (pl) | 2022-04-04 |
Family
ID=59057647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21204490.3T PL3978500T3 (pl) | 2015-12-16 | 2016-12-16 | Sposób wytwarzania tricyklicznych związków inhibitorów pi3k |
| PL16876773T PL3389662T3 (pl) | 2015-12-16 | 2016-12-16 | Sposób wytwarzania trójpierścieniowych związków inhibitorów pi3k oraz sposoby ich zastosowania do leczenia raka |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21204490.3T PL3978500T3 (pl) | 2015-12-16 | 2016-12-16 | Sposób wytwarzania tricyklicznych związków inhibitorów pi3k |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10906918B2 (pl) |
| EP (2) | EP3978500B1 (pl) |
| CN (2) | CN113999249B (pl) |
| AU (4) | AU2016369528B2 (pl) |
| DK (1) | DK3389662T3 (pl) |
| ES (2) | ES2972605T3 (pl) |
| HR (1) | HRP20220227T1 (pl) |
| MY (1) | MY196817A (pl) |
| PL (2) | PL3978500T3 (pl) |
| SG (1) | SG11201804204QA (pl) |
| WO (1) | WO2017106647A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY196817A (en) | 2015-12-16 | 2023-05-03 | Genentech Inc | Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer |
| US10767006B2 (en) * | 2017-06-07 | 2020-09-08 | Medtronic, Inc. | Hydrogenation of tyrosine derived polyarylates |
| KR20260008165A (ko) * | 2019-02-12 | 2026-01-15 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| TWI843838B (zh) * | 2019-04-02 | 2024-06-01 | 美商Ｍｅｒｙｘ股份有限公司 | 激酶抑制劑之多晶型、含有該化合物之醫藥組成物、製備方法、及應用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| GB2356630A (en) * | 1999-11-10 | 2001-05-30 | Merck & Co Inc | Intermediates used in the preparation of tetrahydronaphthyridine |
| KR20040024564A (ko) | 2001-07-12 | 2004-03-20 | 아베시아 리미티드 | 마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법 |
| WO2009116069A2 (en) | 2008-02-04 | 2009-09-24 | Ipca Laboratories Limited | Process for preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(2- methoxyphenoxy) ethyl] amino]-2-propanol |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| MX2012002059A (es) * | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
| JP5585257B2 (ja) * | 2010-07-16 | 2014-09-10 | 株式会社リコー | 画像形成装置、機器システム、プログラム管理方法、プログラム |
| SG188439A1 (en) * | 2010-10-01 | 2013-05-31 | Novartis Ag | Manufacturing process for pyrimidine derivatives |
| TW201500358A (zh) | 2010-12-16 | 2015-01-01 | 赫夫門羅氏藥廠股份有限公司 | 三環ｐｉ３ｋ抑制劑化合物及其使用方法 |
| MX364558B (es) * | 2013-10-04 | 2019-04-29 | Univ Basel | INHIBIDORES DE PI3K Y mTOR CONFORMACIONALMENTE RESTRINGIDOS. |
| MY196817A (en) | 2015-12-16 | 2023-05-03 | Genentech Inc | Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer |
-
2016
- 2016-12-16 MY MYPI2018702031A patent/MY196817A/en unknown
- 2016-12-16 EP EP21204490.3A patent/EP3978500B1/en active Active
- 2016-12-16 WO PCT/US2016/067174 patent/WO2017106647A1/en not_active Ceased
- 2016-12-16 US US15/780,328 patent/US10906918B2/en active Active
- 2016-12-16 ES ES21204490T patent/ES2972605T3/es active Active
- 2016-12-16 PL PL21204490.3T patent/PL3978500T3/pl unknown
- 2016-12-16 PL PL16876773T patent/PL3389662T3/pl unknown
- 2016-12-16 ES ES16876773T patent/ES2907574T3/es active Active
- 2016-12-16 SG SG11201804204QA patent/SG11201804204QA/en unknown
- 2016-12-16 CN CN202111170407.5A patent/CN113999249B/zh active Active
- 2016-12-16 AU AU2016369528A patent/AU2016369528B2/en active Active
- 2016-12-16 EP EP16876773.9A patent/EP3389662B1/en active Active
- 2016-12-16 HR HRP20220227TT patent/HRP20220227T1/hr unknown
- 2016-12-16 DK DK16876773.9T patent/DK3389662T3/da active
- 2016-12-16 CN CN201680073496.2A patent/CN108697713B/zh active Active
-
2020
- 2020-12-08 US US17/115,095 patent/US11643421B2/en active Active
-
2021
- 2021-07-05 AU AU2021204704A patent/AU2021204704B2/en active Active
-
2023
- 2023-03-24 US US18/189,623 patent/US20230242550A1/en not_active Abandoned
- 2023-06-29 AU AU2023204160A patent/AU2023204160A1/en not_active Abandoned
-
2025
- 2025-01-22 AU AU2025200428A patent/AU2025200428A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201804204QA (en) | 2018-06-28 |
| US11643421B2 (en) | 2023-05-09 |
| CN108697713B (zh) | 2021-10-26 |
| US20180354970A1 (en) | 2018-12-13 |
| CN108697713A (zh) | 2018-10-23 |
| EP3389662B1 (en) | 2021-12-01 |
| WO2017106647A1 (en) | 2017-06-22 |
| CN113999249A (zh) | 2022-02-01 |
| CN113999249B (zh) | 2025-03-25 |
| US20230242550A1 (en) | 2023-08-03 |
| US10906918B2 (en) | 2021-02-02 |
| AU2016369528B2 (en) | 2021-04-22 |
| EP3978500A1 (en) | 2022-04-06 |
| HRP20220227T1 (hr) | 2022-04-29 |
| CA3008394A1 (en) | 2017-06-22 |
| EP3978500B1 (en) | 2023-11-22 |
| EP3389662A4 (en) | 2019-05-08 |
| AU2016369528A1 (en) | 2018-06-07 |
| DK3389662T3 (da) | 2022-02-28 |
| ES2972605T3 (es) | 2024-06-13 |
| ES2907574T3 (es) | 2022-04-25 |
| AU2023204160A1 (en) | 2023-07-20 |
| HK1256363A1 (zh) | 2019-09-20 |
| US20210253599A1 (en) | 2021-08-19 |
| EP3389662A1 (en) | 2018-10-24 |
| AU2025200428A1 (en) | 2025-02-13 |
| AU2021204704B2 (en) | 2023-04-06 |
| MY196817A (en) | 2023-05-03 |
| PL3978500T3 (pl) | 2024-03-11 |
| EP3978500C0 (en) | 2023-11-22 |
| AU2021204704A1 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258154A (en) | Pyrazolopyrimidine history as btk inhibitors for cancer treatment | |
| IL266847A (en) | Cancer treatment methods involving tigit-binding agents | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL255189A0 (en) | Cancer treatment methods | |
| IL258955B2 (en) | Cancer treatment preparations and methods | |
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| IL263678B (en) | Compounds for use in the treatment of breast cancer +ar | |
| EP3169363A4 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| IL253979A0 (en) | Methods, preparations and kits for cancer treatment | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| IL254842A0 (en) | Therapeutic preparations and methods for use in cancer treatment | |
| IL262342A (en) | Cancer treatment methods | |
| HUE050567T2 (hu) | Triciklusos heterociklusok rák kezelésére | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| IL263793A (en) | Compounds and preparations for the treatment of cancer | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| EP4169918B8 (en) | Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer | |
| ZA201808232B (en) | Compositions and methods for the treatment of cancer | |
| EP3487999A4 (en) | METHODS OF TREATING CANCER | |
| PL3389662T3 (pl) | Sposób wytwarzania trójpierścieniowych związków inhibitorów pi3k oraz sposoby ich zastosowania do leczenia raka | |
| EP3303289A4 (en) | Compounds and methods for treating cancer | |
| GB201514018D0 (en) | Novel tricyclic compounds and their use in the treatment of cancer | |
| HK1260504A1 (en) | Compositions and methods for treatment of cancer | |
| EP3125903A4 (en) | Method for use of homopiperazinium compounds in the treatment of cancer | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer |